EBUS-FNA Cytologic-Histologic Correlation of PD-L1 Immunohistochemistry In Non-Small Cell Lung Cancer

Publication date: Available online 6 April 2020Source: Journal of the American Society of CytopathologyAuthor(s): Rachel Jug, Coral X. Giovacchini, Beiyu Liu, Cindy Green, Jeffrey M. Clarke, Kamran Mahmood, Elizabeth N. Pavlisko
Source: Journal of the American Society of Cytopathology - Category: Cytology Source Type: research

Related Links:

Publication date: Available online 24 May 2020Source: Journal of Vascular and Interventional RadiologyAuthor(s): Kasey Halsey, Jing Wu, Chang Su, Ben Hsieh, Thomas Yi, Scott A. Collins, Benjamin Kimia, Paul J. Zhang, Terrance Healey, Zishu Zhang, Harrison X. Bai
Source: Journal of Vascular and Interventional Radiology - Category: Radiology Source Type: research
Condition:   Non Small Cell Lung Cancer Intervention:   Drug: TQ-B3139 Sponsor:   Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 23 May 2020Source: Practical Radiation OncologyAuthor(s): Roman O. Kowalchuk, Michael R. Waters, K. Martin Richardson, Kelly M. Spencer, James M. Larner, C.R. Kersh
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Innate and acquired resistance is the principle factor limiting the efficacy of tyrosine kinase inhibitors (TKIs) in lung cancer. We have observed a dramatic upregulation of the cell surface co-receptor neuropilin-2b (NRP2b) in lung cancers clinically treated with TKIs correlating with acquired resistance. We hypothesize that NRP2b plays a functional role in acquired TKI resistance.
Source: The Journal of Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Source Type: research
n Chien-Chih Chiu Lung cancer is one of the deadliest cancers worldwide due to chemoresistance in patients with late-stage disease. Quinoline derivatives show biological activity against HIV, malaria, bacteriuria, and cancer. DFIQ is a novel synthetic quinoline derivative that induces cell death in both in vitro and in vivo zebrafish xenograft models. DFIQ induced cell death, including apoptosis, and the IC50 values were 4.16 and 2.31 μM at 24 and 48 h, respectively. DFIQ was also found to induce apoptotic protein cleavage and DNA damage, reduce cell cycle-associated protein expression, and disrupt reactive ox...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Condition:   Non Small Cell Lung Cancer Intervention:   Drug: TQ-B3139 Sponsor:   Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSIONS miR-4448 can inhibit A549 cell proliferation and metastasis. miR-4448 in exosomes has the potential to serve as a diagnostic marker of patients with adenocarcinoma metastasis. PMID: 32444593 [PubMed - as supplied by publisher]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
This article aims to provide an overview of the efficacy and safety outcomes with durvalumab in patients with stage III NSCLC and identify management strategies for potential adverse events (AEs). METHODS: A review of published literature and guidelines was performed to evaluate durvalumab clinical outcomes and AE management strategies. FINDINGS: Durvalumab has established efficacy in patients with unresectable stage III NSCLC and is now the standard of care following CRT. Nurses need to be trained to recognize potential immune-related AEs in patients treated with immune checkpoint inhibitors. PMID: 32...
Source: Clinical Journal of Oncology Nursing - Category: Nursing Authors: Tags: Clin J Oncol Nurs Source Type: research
Advanced non-small cell lung cancer (NSCLC) is the most common type of lung cancer, with a poor prognosis and no known cure. Survival time is often short because of limited treatment options. Recent advances i...
Source: Journal of Hematology and Oncology - Category: Hematology Authors: Tags: Review Source Type: research
More News: Cancer | Cancer & Oncology | Cytology | Lung Cancer | Non-Small Cell Lung Cancer